Drug Type Small molecule drug |
Synonyms CWP 232291, CWP 291, CWP-291 + [1] |
Target |
Mechanism Wnt ligand inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory acute myeloid leukemia | Phase 2 | US | 06 Feb 2017 | |
Refractory acute myeloid leukemia | Phase 2 | KR | 06 Feb 2017 | |
Relapsing acute myeloid leukemia | Phase 2 | US | 06 Feb 2017 | |
Relapsing acute myeloid leukemia | Phase 2 | KR | 06 Feb 2017 | |
Plasma cell myeloma refractory | Phase 1 | US | 19 Oct 2015 | |
Plasma cell myeloma refractory | Phase 1 | KR | 19 Oct 2015 | |
Chronic Myelomonocytic Leukemia | Phase 1 | US | 01 Jul 2011 | |
Chronic Myelomonocytic Leukemia | Phase 1 | KR | 01 Jul 2011 | |
Myelodysplastic Syndromes | Phase 1 | US | 01 Jul 2011 | |
Myelodysplastic Syndromes | Phase 1 | KR | 01 Jul 2011 |
Phase 1 | 69 | jkxugzyxhe(zstdkwgmwf) = >3 patients (5%) were pneumonia (n = 8, 12%); hypophosphatemia (n = 6, 8%); leukocytosis, nausea, cellulitis, sepsis, and hypokalemia (n = 5 each, 7% each); and hypertension (n = 4, 6%). qhjlnxzuov (wgvdstddkk ) View more | Positive | 12 May 2020 |